Literature DB >> 17517860

Multiple consecutive lavage samplings reveal greater burden of disease and provide direct access to the nontypeable Haemophilus influenzae biofilm in experimental otitis media.

Magali Leroy1, Howard Cabral, Marisol Figueira, Valérie Bouchet, Heather Huot, Sanjay Ram, Stephen I Pelton, Richard Goldstein.   

Abstract

The typically recovered quantity of nontypeable Haemophilus influenzae (NTHi) bacteria in an ex vivo middle ear (ME) aspirate from the chinchilla model of experimental otitis media is insufficient for direct analysis of gene expression by microarray or of lipopolysaccharide glycoforms by mass spectrometry. This prompted us to investigate a strategy of multiple consecutive lavage samplings to increase ex vivo bacterial recovery. As multiple consecutive lavage samples significantly increased the total number of bacterial CFU collected during nasopharyngeal colonization or ME infection, this led us to evaluate whether bacteria sequentially acquired from consecutive lavages were similar. Comparative observation of complete ex vivo sample series by microscopy initially revealed ME inflammatory fluid consisting solely of planktonic-phase NTHi. In contrast, subsequent lavage samplings of the same infected ear revealed the existence of bacteria in two additional growth states, filamentous and biofilm encased. Gene expression analysis of such ex vivo samples was in accord with different bacterial growth phases in sequential lavage specimens. The existence of morphologically distinct NTHi subpopulations with varying levels of gene expression indicates that the pooling of specimens requires caution until methods for their separation are developed. This study based on multiple consecutive lavages is consistent with prior reports that NTHi forms a biofilm in vivo, describes the means to directly acquire ex vivo biofilm samples without sacrificing the animal, and has broad applicability for a study of mucosal infections. Moreover, this approach revealed that the actual burden of bacteria in experimental otitis media is significantly greater than was previously reported. Such findings may have direct implications for antibiotic treatment and vaccine development against NTHi.

Entities:  

Mesh:

Year:  2007        PMID: 17517860      PMCID: PMC1952021          DOI: 10.1128/IAI.00318-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  78 in total

Review 1.  Biofilms as complex differentiated communities.

Authors:  P Stoodley; K Sauer; D G Davies; J W Costerton
Journal:  Annu Rev Microbiol       Date:  2002-01-30       Impact factor: 15.500

2.  Isolation and characterization of mutants of Haemophilus influenzae deficient in an adenosine 5'-triphosphate-dependent deoxyribonuclease activity.

Authors:  K W Wilcox; H O Smith
Journal:  J Bacteriol       Date:  1975-05       Impact factor: 3.490

3.  A characterization of DNA release in Pseudomonas aeruginosa cultures and biofilms.

Authors:  Marie Allesen-Holm; Kim Bundvig Barken; Liang Yang; Mikkel Klausen; Jeremy S Webb; Staffan Kjelleberg; Søren Molin; Michael Givskov; Tim Tolker-Nielsen
Journal:  Mol Microbiol       Date:  2006-02       Impact factor: 3.501

4.  High rates of recombination in otitis media isolates of non-typeable Haemophilus influenzae.

Authors:  Alison J Cody; Dawn Field; Edward J Feil; Suzanna Stringer; Mary E Deadman; Anthony G Tsolaki; Brett Gratz; Valérie Bouchet; Richard Goldstein; Derek W Hood; E Richard Moxon
Journal:  Infect Genet Evol       Date:  2003-05       Impact factor: 3.342

5.  Induction of heritable new type in type specific strains of H. influenzae.

Authors:  H E ALEXANDER; G LEIDY
Journal:  Proc Soc Exp Biol Med       Date:  1951-11

6.  Sialic acid in the lipopolysaccharide of Haemophilus influenzae: strain distribution, influence on serum resistance and structural characterization.

Authors:  D W Hood; K Makepeace; M E Deadman; R F Rest; P Thibault; A Martin; J C Richards; E R Moxon
Journal:  Mol Microbiol       Date:  1999-08       Impact factor: 3.501

7.  Elaboration of type b capsule by Haemophilus influenzae as a determinant of pathogenicity and impaired killing by trimethoprim-sulfamethoxazole.

Authors:  R Yogev; E R Moxon
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

Review 8.  The burden of otitis media.

Authors:  J O Klein
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

9.  Nontypeable Haemophilus influenzae gene expression induced in vivo in a chinchilla model of otitis media.

Authors:  Kevin M Mason; Robert S Munson; Lauren O Bakaletz
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

10.  Nontypeable Haemophilus influenzae strain 2019 produces a biofilm containing N-acetylneuraminic acid that may mimic sialylated O-linked glycans.

Authors:  L L Greiner; H Watanabe; N J Phillips; J Shao; A Morgan; A Zaleski; B W Gibson; M A Apicella
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

View more
  14 in total

Review 1.  Bacterial biofilms in the upper airway - evidence for role in pathology and implications for treatment of otitis media.

Authors:  Lauren O Bakaletz
Journal:  Paediatr Respir Rev       Date:  2012-05-27       Impact factor: 2.726

2.  Morphological plasticity promotes resistance to phagocyte killing of uropathogenic Escherichia coli.

Authors:  Dennis J Horvath; Birong Li; Travis Casper; Santiago Partida-Sanchez; David A Hunstad; Scott J Hultgren; Sheryl S Justice
Journal:  Microbes Infect       Date:  2010-12-21       Impact factor: 2.700

3.  Intercellular adhesion and biocide resistance in nontypeable Haemophilus influenzae biofilms.

Authors:  Era A Izano; Suhagi M Shah; Jeffrey B Kaplan
Journal:  Microb Pathog       Date:  2009-02-04       Impact factor: 3.738

4.  Evaluation of the kinetics and mechanism of action of anti-integration host factor-mediated disruption of bacterial biofilms.

Authors:  M Elizabeth Brockson; Laura A Novotny; Elaine M Mokrzan; Sankalp Malhotra; Joseph A Jurcisek; Rabia Akbar; Aishwarya Devaraj; Steven D Goodman; Lauren O Bakaletz
Journal:  Mol Microbiol       Date:  2014-08-19       Impact factor: 3.501

Review 5.  Options and Limitations in Clinical Investigation of Bacterial Biofilms.

Authors:  Maria Magana; Christina Sereti; Anastasios Ioannidis; Courtney A Mitchell; Anthony R Ball; Emmanouil Magiorkinis; Stylianos Chatzipanagiotou; Michael R Hamblin; Maria Hadjifrangiskou; George P Tegos
Journal:  Clin Microbiol Rev       Date:  2018-04-04       Impact factor: 26.132

6.  Therapeutic Transcutaneous Immunization with a Band-Aid Vaccine Resolves Experimental Otitis Media.

Authors:  Laura A Novotny; John D Clements; Lauren O Bakaletz
Journal:  Clin Vaccine Immunol       Date:  2015-05-27

7.  Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization.

Authors:  Laura A Novotny; John D Clements; Lauren O Bakaletz
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

8.  Application of capillary electrophoresis mass spectrometry and liquid chromatography multiple-step tandem electrospray mass spectrometry to profile glycoform expression during Haemophilus influenzae pathogenesis in the chinchilla model of experimental otitis media.

Authors:  Susanna L Lundström; Jianjun Li; Martin Månsson; Marisol Figueira; Magali Leroy; Richard Goldstein; Derek W Hood; E Richard Moxon; James C Richards; Elke K H Schweda
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

9.  Characterization of a ferrous iron-responsive two-component system in nontypeable Haemophilus influenzae.

Authors:  Kendra H Steele; Lauren H O'Connor; Nicole Burpo; Katharina Kohler; Jason W Johnston
Journal:  J Bacteriol       Date:  2012-09-07       Impact factor: 3.490

10.  The periplasmic disulfide oxidoreductase DsbA contributes to Haemophilus influenzae pathogenesis.

Authors:  Charles V Rosadini; Sandy M S Wong; Brian J Akerley
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.